1. Greef, B. and T. Eisen, Medical treatment of renal cancer: new horizons. Br J Cancer, 2016. 115(5): p. 505-16.
2. Siegel, R.L., et al., Cancer Statistics, 2021. CA Cancer J Clin, 2021. 71(1): p. 7-33.
3. Ferlay, J., et al., Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer, 2018. 103: p. 356-387.
4. Moch, H., et al., The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 2016. 70(1): p. 93-105.
5. Ljungberg, B., et al., European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol, 2019. 75(5): p. 799-810.
6. Perry, R.P. and D.E. Kelley, Existence of methylated messenger RNA in mouse L cells. Cell, 1974. 1(1): p. 37-42.
7. Desrosiers, R., K. Friderici, and F. Rottman, Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A, 1974. 71(10): p. 3971-5.
8. Lee, M., B. Kim, and V.N. Kim, Emerging roles of RNA modification: m(6)A and U-tail. Cell, 2014. 158(5): p. 980-987.
9. Shi, H., et al., YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res, 2017. 27(3): p. 315-328.
10. Dai, F., et al., Crosstalk between RNA m(6)A Modification and Non-coding RNA Contributes to Cancer Growth and Progression. Mol Ther Nucleic Acids, 2020. 22: p. 62-71.
11. Chen, X.Y., J. Zhang, and J.S. Zhu, The role of m(6)A RNA methylation in human cancer. Mol Cancer, 2019. 18(1): p. 103.
12. Zhao, Q., et al., m(6)A RNA modification modulates PI3K/Akt/mTOR signal pathway in Gastrointestinal Cancer. Theranostics, 2020. 10(21): p. 9528-9543.
13. Chen, J., et al., Identification of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of clear cell renal carcinoma. Cancer Cell Int, 2020. 20: p. 157.
14. Wang, Y., et al., Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma. Cancer Cell Int, 2021. 21(1): p. 46.
15. Meyer, K.D., et al., 5' UTR m(6)A Promotes Cap-Independent Translation. Cell, 2015. 163(4): p. 999-1010.
16. Pincheira, R., Q. Chen, and J.T. Zhang, Identification of a 170-kDa protein over-expressed in lung cancers. Br J Cancer, 2001. 84(11): p. 1520-7.
17. Haybaeck, J., et al., Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res, 2010. 30(4): p. 1047-55.
18. Chen, G. and M.M. Burger, p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer, 2004. 112(3): p. 393-8.
19. Spilka, R., et al., EIF3A is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cell Oncol (Dordr), 2014. 37(4): p. 253-67.
20. Dong, Z., et al., Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene, 2004. 23(21): p. 3790-801.
21. Spilka, R., et al., Overexpression of EIF3A in Squamous Cell Carcinoma of the Oral Cavity and Its Putative Relation to Chemotherapy Response. J Oncol, 2012. 2012: p. 901956.
22. Chen, K., et al., Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer. Clin Cancer Res, 2017. 23(13): p. 3428-3441.
23. Subramanian, A., et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 2005. 102(43): p. 15545-50.
24. Vasaikar, S.V., et al., LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res, 2018. 46(D1): p. D956-D963.
25. Vuong, L., et al., Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. Cancer Discov, 2019. 9(10): p. 1349-1357.
26. Thompson, R.H., et al., PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res, 2007. 13(6): p. 1757-61.
27. Ghatalia, P., et al., Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. J Immunother Cancer, 2019. 7(1): p. 139.
28. Zhao, X., et al., Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. Cancer Lett, 2015. 362(2): p. 192-8.
29. Shriwas, O., et al., The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy. Front Oncol, 2020. 10: p. 612337.
30. Lan, Q., et al., The Critical Role of RNA m(6)A Methylation in Cancer. Cancer Res, 2019. 79(7): p. 1285-1292.
31. Li, X., et al., The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma. Oncotarget, 2017. 8(56): p. 96103-96116.
32. Wang, Q., et al., Identification of METTL14 in Kidney Renal Clear Cell Carcinoma Using Bioinformatics Analysis. Dis Markers, 2019. 2019: p. 5648783.
33. Zhao, J. and L. Lu, Interplay between RNA Methylation EraserFTO and Writer METTL3in Renal Clear Cell Carcinoma Patient Survival. Recent Pat Anticancer Drug Discov, 2021.
34. Yin, J.Y., et al., EIF3A: A new anticancer drug target in the eIF family. Cancer Lett, 2018. 412: p. 81-87.
35. Xu, T.R., et al., Eukaryotic translation initiation factor 3, subunit a, regulates the extracellular signal-regulated kinase pathway. Mol Cell Biol, 2012. 32(1): p. 88-95.
36. Lane, D.J., et al., N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (EIF3A) during cellular stress caused by iron depletion. PLoS One, 2013. 8(2): p. e57273.
37. Loar, J.W., et al., Genetic and biochemical interactions among Yar1, Ltv1 and Rps3 define novel links between environmental stress and ribosome biogenesis in Saccharomyces cerevisiae. Genetics, 2004. 168(4): p. 1877-89.
38. Seiser, R.M., et al., Ltv1 is required for efficient nuclear export of the ribosomal small subunit in Saccharomyces cerevisiae. Genetics, 2006. 174(2): p. 679-91.
39. Ruggero, D. and P.P. Pandolfi, Does the ribosome translate cancer? Nat Rev Cancer, 2003. 3(3): p. 179-92.
40. Stumpf, C.R. and D. Ruggero, The cancerous translation apparatus. Curr Opin Genet Dev, 2011. 21(4): p. 474-83.
41. Collins, J.C., et al., Ribosome biogenesis factor Ltv1 chaperones the assembly of the small subunit head. J Cell Biol, 2018. 217(12): p. 4141-4154.
42. Ghalei, H., et al., Hrr25/CK1delta-directed release of Ltv1 from pre-40S ribosomes is necessary for ribosome assembly and cell growth. J Cell Biol, 2015. 208(6): p. 745-59.
43. Rosenberg, L.H., et al., Therapeutic targeting of casein kinase 1delta in breast cancer. Sci Transl Med, 2015. 7(318): p. 318ra202.